Concepedia

Andreas Weihofen

AW

Statistics

Publications

25

Citations

3.8K

H-Index

19

Active since

2000

Affiliations

Biogen (United States)(Current)

Brigham and Women's Hospital

Harvard University

Ionis Pharmaceuticals (United States)

Compass (United States)

Andreas Weihofen is an author at Biogen (United States) specializing in life sciences, parkinson disease, and neurodegenerative diseases.

ORCID

Publications per year

2000–2024

25

Publications

25

Dopamine covalently modifies and functionally inactivates parkin

Matthew J. LaVoie, Beth L. Ostaszewski, Andreas Weihofen et al. · Nature Medicine · 2005 · 717 citations

, , +10

Identification of Signal Peptide Peptidase, a Presenilin-Type Aspartic Protease

Andreas Weihofen, Kathleen L. Binns, Marius K. Lemberg et al. · Science · 2002 · 529 citations

, , +16

The mitochondrial intramembrane protease PARL cleaves human Pink1 to regulate Pink1 trafficking

Holger Lorenz, Andreas Weihofen, Dennis J. Selkoe et al. · Journal of Neurochemistry · 2011 · 375 citations

, , +17

Pink1 Forms a Multiprotein Complex with Miro and Milton, Linking Pink1 Function to Mitochondrial Trafficking

Andreas Weihofen, Kelly Jean Thomas Craig, Beth L. Ostaszewski et al. · Biochemistry · 2009 · 290 citations · Full text

, , +16

LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson’s Disease Mouse Model

Hien Zhao, Neena John, Vedad Delic et al. · Molecular Therapy — Nucleic Acids · 2017 · 217 citations · Full text

, , +17

1–5 of 25